FAP and familial pancreatic carcinoma: Develop combinatorial regimens: Given the association between hmmyCAF abundance and immunotherapy resistance (high POSTN correlates with PFS HR = 0.66, p = 0.02; Figure 6E), combining FAP‐targeted CAF depletion with anti‐PD‐1 therapy could simultaneously disrupt physical barriers and molecular inhibition—mirroring pancreatic cancer models where this approach doubled survival.[53]